The first inhibitor of angiogenesis to be approved by the FDA was bevacizumab (Avastin), a monoclonal antibody used to treat colorectal cancer that binds to VEGF-A and inhibits interaction with their receptors. The gene discussed is VEGFA; the disease is colorectal cancer.